Study shows personalized mRNA vaccine cuts melanoma recurrence risk in half after five years
A Moderna experimental vaccine tailored to each patient's tumor cut odds of deadly skin cancer returning — and new five-year data shows the results holding.
A Moderna experimental vaccine tailored to each patient's tumor cut odds of deadly skin cancer returning — and new five-year data shows the results holding.
What's Your Reaction?
